Cat. No.: HY-P0267

Melanotan (MT)-II

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Melanotan (MT)-II is a melanocortin receptor agonist. Melanotan (MT)-II activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.97%
CAS No.: 121062-08-6
Formule: C₅₀H₆₉N₁₅O₉
Masse moléculaire:1024.18

Stockage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Melanotan (MT)-II Chemical Structure

CAS No.: 121062-08-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) Melanotan (MT)-II

Cell Rep. 2024 Nov 19;43(12):114983. [Abstract]

Customer Validation & Images

In Vivo Efficacy Study

In Vivo Efficacy Study

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

MC3R

MC4R

Voir tous les produits spécifiques à Isoform Melanocortin Receptor :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	EC₅₀	110 nM Compound: MT-II	Agonist activity at human MC1 receptor expressed in A375 cells assessed as intracellular cAMP accumulation using [3H]-cAMP by luminescence counting Agonist activity at human MC1 receptor expressed in A375 cells assessed as intracellular cAMP accumulation using [3H]-cAMP by luminescence counting	[PMID: 26218460]
A-375	IC₅₀	6.7 nM Compound: MT-II	Antagonist activity at human MC1 receptor expressed in A375 cells assessed as inhibition of MT-II-induced intracellular cAMP accumulation using [3H]-cAMP by luminescence counting Antagonist activity at human MC1 receptor expressed in A375 cells assessed as inhibition of MT-II-induced intracellular cAMP accumulation using [3H]-cAMP by luminescence counting	[PMID: 26218460]
HEK293	EC₅₀	0.02 nM Compound: MTII	Activity in mouse melanocortin-1 receptor stably expressed in HEK293 cells Activity in mouse melanocortin-1 receptor stably expressed in HEK293 cells	[PMID: 12477357]
HEK293	EC₅₀	0.021 nM Compound: MTII	Agonist activity at mouse MC1R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC1R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.03 nM Compound: MT-II	Activity at mouse MC1R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC1R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.04 nM Compound: MTII	Agonist activity at mouse MC4R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC4R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.05 nM Compound: MTII	Agonist activity at mouse melanocortin-4 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-4 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	EC₅₀	0.06 nM Compound: MT-II	Activity at mouse MC4R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC4R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.087 nM Compound: MTII	Activity in mouse melanocortin-4 receptor stably expressed in HEK293 cells Activity in mouse melanocortin-4 receptor stably expressed in HEK293 cells	[PMID: 12477357]
HEK293	EC₅₀	0.16 nM Compound: MTII	Activity in mouse melanocortin-3 receptor (mMC3R) stably expressed in HEK293 cells Activity in mouse melanocortin-3 receptor (mMC3R) stably expressed in HEK293 cells	[PMID: 12477357]
HEK293	EC₅₀	0.16 nM Compound: MTII	Activity in mouse melanocortin-5 receptor stably expressed in HEK293 cells Activity in mouse melanocortin-5 receptor stably expressed in HEK293 cells	[PMID: 12477357]
HEK293	EC₅₀	0.17 nM Compound: MTII	Agonist activity at mouse MC3R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC3R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.18 nM Compound: MTII	Agonist activity at mouse MC5R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC5R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.18 nM Compound: MT-II	Activity at mouse MC3R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC3R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.19 nM Compound: MT-II	Activity at mouse MC5R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC5R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.22 nM Compound: MTII	Agonist activity at mouse melanocortin-1 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-1 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	EC₅₀	0.3 nM Compound: 17	Activity against hMC1R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC1R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	EC₅₀	0.3 nM Compound: MTII	Activity at hMC1R transfected in HEK293 cells assessed as intracellular cAMP accumulation Activity at hMC1R transfected in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 17154518]
HEK293	EC₅₀	0.3 nM Compound: MTII	Agonist activity at human MC1R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level Agonist activity at human MC1R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level	[PMID: 19473029]
HEK293	EC₅₀	0.3 nM Compound: MT-II	Agonist activity at human MC1 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation Agonist activity at human MC1 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 18088090]
HEK293	EC₅₀	0.35 nM Compound: MTII	Agonist activity at mouse melanocortin-3 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-3 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	EC₅₀	0.57 nM Compound: MTII	Agonist activity at mouse melanocortin-5 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-5 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	EC₅₀	1 nM Compound: MT-II	Activity at human MC1R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC1R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	1.02 nM Compound: MT-II	Activity at human MC1 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Activity at human MC1 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	EC₅₀	1.02 nM Compound: MT-II	Agonist activity at human MC1R expressed in HEK293 cells assessed as increase in intracellular cAMP accumulation Agonist activity at human MC1R expressed in HEK293 cells assessed as increase in intracellular cAMP accumulation	[PMID: 21486697]
HEK293	EC₅₀	1.8 nM Compound: MT-II	Agonist activity at human melanocortin 1 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 1 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	1.8 nM Compound: MT-II	Agonist activity at human melanocortin 3 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 3 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	1.85 nM Compound: MT-II	Agonist activity at human MC3 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation Agonist activity at human MC3 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 18088090]
HEK293	EC₅₀	1.9 nM Compound: 17	Activity against hMC3R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC3R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	EC₅₀	1.9 nM Compound: MTII	Activity at hMC3R transfected in HEK293 cells assessed as intracellular cAMP accumulation Activity at hMC3R transfected in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 17154518]
HEK293	EC₅₀	1.9 nM Compound: MTII	Agonist activity at human MC3R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level Agonist activity at human MC3R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level	[PMID: 19473029]
HEK293	EC₅₀	2.1 nM Compound: MT-II	Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	EC₅₀	2.1 nM Compound: MT-II	Agonist activity at human MC4R expressed in HEK293 cells assessed as intracellular cAMP accumulation Agonist activity at human MC4R expressed in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 21486697]
HEK293	EC₅₀	2.3 nM Compound: MT-II	Activity at human MC4R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC4R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	2.4 nM Compound: MT-II	Activity at human MC3R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC3R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	2.87 nM Compound: MT-II	Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 18088090]
HEK293	EC₅₀	2.9 nM Compound: 17	Activity against hMC4R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC4R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	EC₅₀	2.9 nM Compound: MT-II	Agonist activity at human melanocortin 4 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 4 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	2.9 nM Compound: MTII	Activity at hMC4R transfected in HEK293 cells assessed as intracellular cAMP accumulation Activity at hMC4R transfected in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 17154518]
HEK293	EC₅₀	2.9 nM Compound: MTII	Agonist activity at human MC4R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level Agonist activity at human MC4R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level	[PMID: 19473029]
HEK293	EC₅₀	3.1 nM Compound: MT-II	Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells assessed as increase in cAMP accumulation after 30 mins by luminescent enzymatic complementation based assay Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells assessed as increase in cAMP accumulation after 30 mins by luminescent enzymatic complementation based assay	[PMID: 28972753]
HEK293	EC₅₀	3.3 nM Compound: 17	Activity against hMC5R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC5R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	EC₅₀	3.3 nM Compound: MT-II	Agonist activity at human melanocortin 5 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 5 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	3.3 nM Compound: MTII	Activity at hMC5R transfected in HEK293 cells assessed as intracellular cAMP accumulation Activity at hMC5R transfected in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 17154518]
HEK293	EC₅₀	3.3 nM Compound: MTII	Agonist activity at human MC5R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level Agonist activity at human MC5R expressed in HEK293 cells assessed as stimulation of intracellular cAMP level	[PMID: 19473029]
HEK293	EC₅₀	3.3 nM Compound: MT-II	Agonist activity at human MC5 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation Agonist activity at human MC5 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 18088090]
HEK293	EC₅₀	33.9 nM Compound: MT-II	Agonist activity at EYFP-fused human MC3R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay Agonist activity at EYFP-fused human MC3R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay	[PMID: 28972753]
HEK293	EC₅₀	33.9 nM Compound: MT-II	Agonist activity at EYFP-fused human MC5R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay Agonist activity at EYFP-fused human MC5R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay	[PMID: 28972753]
HEK293	EC₅₀	5.1 nM Compound: MT-II	Activity at human MC3 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Activity at human MC3 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	EC₅₀	5.1 nM Compound: MT-II	Agonist activity at human MC3R expressed in HEK293 cells assessed as intracellular cAMP accumulation Agonist activity at human MC3R expressed in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 21486697]
HEK293	EC₅₀	5.7 nM Compound: MT-II	Antagonist activity at human MC5 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Antagonist activity at human MC5 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	EC₅₀	5.7 nM Compound: MT-II	Agonist activity at human MC5R expressed in HEK293 cells assessed as intracellular cAMP accumulation Agonist activity at human MC5R expressed in HEK293 cells assessed as intracellular cAMP accumulation	[PMID: 21486697]
HEK293	EC₅₀	8 nM Compound: MT-II	Activity at human MC5R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC5R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	8.6 nM Compound: MT-II	Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay	[PMID: 28972753]
HEK293	IC₅₀	0.1 nM Compound: MT-II	Displacement of [125I]NDP-alpha-MSH from human MC1R expressed in HEK293 cells Displacement of [125I]NDP-alpha-MSH from human MC1R expressed in HEK293 cells	[PMID: 16931008]
HEK293	IC₅₀	0.2 nM Compound: 17	Inhibitory activity against hMC1R transfected in HEK293 cells Inhibitory activity against hMC1R transfected in HEK293 cells	[PMID: 16539382]
HEK293	IC₅₀	0.2 nM Compound: MTII	Displacement of [125I]NDP-alphaMSH from human MC1 receptor expressed in HEK293 cells Displacement of [125I]NDP-alphaMSH from human MC1 receptor expressed in HEK293 cells	[PMID: 17154518]
HEK293	IC₅₀	0.2 nM Compound: MTII	Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC1R expressed in HEK293 cells Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC1R expressed in HEK293 cells	[PMID: 19473029]
HEK293	IC₅₀	0.2 nM Compound: MT-II	Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC1 receptor expressed in HEK293 cells Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC1 receptor expressed in HEK293 cells	[PMID: 18088090]
HEK293	IC₅₀	1 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC1 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC1 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	IC₅₀	1.07 nM Compound: MT-II	Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC4 receptor expressed in HEK293 cells Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC4 receptor expressed in HEK293 cells	[PMID: 18088090]
HEK293	IC₅₀	1.1 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 4 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 4 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	IC₅₀	1.1 nM Compound: 17	Inhibitory activity against hMC4R transfected in HEK293 cells Inhibitory activity against hMC4R transfected in HEK293 cells	[PMID: 16539382]
HEK293	IC₅₀	1.1 nM Compound: MTII	Displacement of [125I]NDP-alphaMSH from human MC4 receptor expressed in HEK293 cells Displacement of [125I]NDP-alphaMSH from human MC4 receptor expressed in HEK293 cells	[PMID: 17154518]
HEK293	IC₅₀	1.1 nM Compound: MTII	Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC4R expressed in HEK293 cells Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC4R expressed in HEK293 cells	[PMID: 19473029]
HEK293	IC₅₀	1.2 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 1 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 1 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	IC₅₀	1.2 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 3 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 3 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	IC₅₀	1.25 nM Compound: MT-II	Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC3 receptor expressed in HEK293 cells Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC3 receptor expressed in HEK293 cells	[PMID: 18088090]
HEK293	IC₅₀	1.3 nM Compound: 17	Inhibitory activity against hMC3R transfected in HEK293 cells Inhibitory activity against hMC3R transfected in HEK293 cells	[PMID: 16539382]
HEK293	IC₅₀	1.3 nM Compound: MTII	Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC3R expressed in HEK293 cells Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC3R expressed in HEK293 cells	[PMID: 19473029]
HEK293	IC₅₀	1.8 nM Compound: MT-II	Displacement of [125I]NDP-alpha-MSH from human MC4R expressed in HEK293 cells Displacement of [125I]NDP-alpha-MSH from human MC4R expressed in HEK293 cells	[PMID: 16931008]
HEK293	IC₅₀	1.9 nM Compound: MT-II	Displacement of [125I]NDP-alpha-MSH from human MC3R expressed in HEK293 cells Displacement of [125I]NDP-alpha-MSH from human MC3R expressed in HEK293 cells	[PMID: 16931008]
HEK293	IC₅₀	2 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC3 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC3 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	IC₅₀	2 nM Compound: MTII	Displacement of [125I]NDP-alphaMSH from human MC3 receptor expressed in HEK293 cells Displacement of [125I]NDP-alphaMSH from human MC3 receptor expressed in HEK293 cells	[PMID: 17154518]
HEK293	IC₅₀	2.3 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC1R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC1R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]
HEK293	IC₅₀	2.3 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]
HEK293	IC₅₀	2.3 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC4 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC4 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	IC₅₀	4.2 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC5R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC5R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]
HEK293	IC₅₀	4.2 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC5 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC5 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	IC₅₀	7 nM Compound: MT-II	Displacement of [125I]NDP-alpha-MSH from human MC5R expressed in HEK293 cells Displacement of [125I]NDP-alpha-MSH from human MC5R expressed in HEK293 cells	[PMID: 16931008]
HEK293	IC₅₀	7.47 nM Compound: MT-II	Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC5 receptor expressed in HEK293 cells Displacement of [125I][Nle4,D-Phe7]alpha-MSH from human MC5 receptor expressed in HEK293 cells	[PMID: 18088090]
HEK293	IC₅₀	7.5 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 5 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 5 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	IC₅₀	7.5 nM Compound: 17	Inhibitory activity against hMC5R transfected in HEK293 cells Inhibitory activity against hMC5R transfected in HEK293 cells	[PMID: 16539382]
HEK293	IC₅₀	7.5 nM Compound: MTII	Displacement of [125I]NDP-alphaMSH from human MC5 receptor expressed in HEK293 cells Displacement of [125I]NDP-alphaMSH from human MC5 receptor expressed in HEK293 cells	[PMID: 17154518]
HEK293	IC₅₀	7.5 nM Compound: MTII	Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC5R expressed in HEK293 cells Displacement of [125I][Nle4,Dphe7]-alpha-MSH from human MC5R expressed in HEK293 cells	[PMID: 19473029]
HEK293	IC₅₀	8 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC3R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC3R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]

In Vivo

Melanotan (MT)-II (20 μM, percutaneous immersion for 2 consecutive days) reverses high-fat diet-induced impairments in recognition memory, reduced exploratory behavior, and anxiety-like symptoms in zebrafish, restoring these indicators to levels comparable to those of animals fed a normal diet^[1].
Melanotan (MT)-II (2.5 μg per day; intracerebroventricular injection; continuous infusion; 7 days) rescues social ability deficits in adult male maternal immune activation (MIA) mice, increasing the social ability index score from 3.1 to 26.3^[2].
Melanotan (MT)-II (0.1-1 nM, microinjected bilaterally into the nucleus accumbens) significantly reduces 24-hour food intake in fasted C57BL/6J mice, produces a significant anorectic effect, and decreases feeding responses in ad libitum-fed mice^[3].
Melanotan (MT)-II (0.1-1 mg/kg, intravenous injection) significantly enhances the overall erectile activity in conscious rats and shortens the latency of the first erectile event in anesthetized rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Danio rerio, longfin phenotype (3-5 months old, ~50:50 male to female ratio, high-fat diet-induced model)^[1]
Dosage:

20 μM
Administration:

percutaneous immersion; two days
Result:

Reversed the significant reduction in time spent in the red (reinforced) arm of the Y-maze (HF + MT-II group spent significantly more time than untreated HF group, matching control group levels).
Reversed the HF diet-induced increase in time spent in the Y-maze start arm (a marker of anxiety).
Restored total object exploration time in the one-trial memory test to control group levels.

Animal Model:

C57BL/6J (4-6 month-old male; maternal immune activation model)^[2]
Dosage:

2.5 μg/day
Administration:

i.c.v.; continuous infusion; 7 days
Result:

Increased sociability index score significantly from 3.1 to 26.3.
Did not produce a significant change in social novelty scores.

Animal Model:

C57BL/6J (male, 2-3 months old, average body weight ~22 g, food-deprived for ~16 hours to induce food-motivated state)^[3]
Dosage:

0.1, 0.3, 1 nM/side
Administration:

bilateral microinjection into nucleus accumbens; single dose
Result:

Significantly decreased food intake at 1, 2, and 4 hours post-injection compared to saline.
Significantly decreased food intake at 24 hours post-injection only at 0.3 nmol/side dose compared to saline.
Showed a significant main effect of drug, time, and drug-time interaction.

Animal Model:

Sprague-Dawley (male, 225-250 g, telemetric intracavernosal pressure monitoring model)^[4]
Dosage:

0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
Administration:

i.v.
Result:

Induced at least one penile erection in 4 out of 5 rats, with a mean 1.6 erections, mean latency to first erection of 2812 s, mean ICPmax of ~360 mmHg, mean AUC of ~2100 mmHg.s, and mean SUM AUC of ~3000 mmHg.s at 0.1 mg/kg.
Induced at least one penile erection in 4 out of 6 rats, with a mean 1.8 erections, mean latency to first erection of 2616 s, mean ICPmax of 472 mmHg, mean AUC of ~2200 mmHg.s, and mean SUM AUC of ~4000 mmHg.s at 0.3 mg/kg.
Induced at least one penile erection in 6 out of 8 rats, with a mean 4.8 erections, mean latency to first erection of 1780 s, mean ICPmax of 548 mmHg, mean AUC of ~2300 mmHg.s, and mean SUM AUC of 10653 mmHg.s at 1 mg/kg.

Chemical Information

CAS No. 121062-08-6
Appearance Solid
Masse moléculaire 1024.18
Formule C₅₀H₆₉N₁₅O₉
Color White to off-white
Sequence

Ac-{Nle}-Asp-His-{d-Phe}-Arg-Trp-Lys-NH2, (2→7)-lactam
Sequence Shortening

Ac-{Nle}-DH-{d-Phe}-RWK-NH2, (2→7)-lactam
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (1)

All In Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell Rep

Tak1 licenses mitochondrial transfer from astrocytes to POMC neurons to maintain glucose and cholesterol homeostasis. [Abstract]

2024 Nov 19;43(12):114983. PMID: 39565693

Melanotan (MT)-II purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 19;43(12):114983. [Abstract]

Artificial cerebrospinal fluid (aCSF) and Melanotan (MT)-II (MTII, 1 μg (in 0.5 μL of aCSF); i.c.v.), an MC3/4R agonist, were administered into the third ventricle of male adult mice. GTT was then performed, and the AUC of the GTT was calculated. Melanotan (MT)-II (MTII, 1 μg (in 0.5 μL of aCSF); i.c.v.), an MC3/4R agonist, largely reversed the impaired glucose tolerance caused by astrocytic Tak1 ablation in GTKO mice. i.c.v., intracerebroventricularly; NS, not significant.

Solvant et solubilité

In Vitro:

H₂O : 6.67 mg/mL (6.51 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9764 mL

4.8820 mL

9.7639 mL

5 mM

0.1953 mL

0.9764 mL

1.9528 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (287 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wekwejt P, et al. Melanotan-II reverses memory impairment induced by a short-term HF diet. Biomed Pharmacother. 2023;165:115129. [Content Brief]

[2]. Minakova E, et al. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS One. 2019;14(1):e0210389. Published 2019 Jan 10. [Content Brief]

[3]. Eliason NL, et al. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289. [Content Brief]

[4]. Giuliano F, et al. The use of telemetry technology to test the proerectile effect of melanotan-II (MT-II) in conscious rats. Eur Urol. 2005 Jul;48(1):145-51; discussion 151-2. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	0.9764 mL	4.8820 mL	9.7639 mL	24.4098 mL
H₂O	5 mM	0.1953 mL	0.9764 mL	1.9528 mL	4.8820 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Melanotan (MT)-II

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Melanotan (MT)-II

Macrocyclic Compound Library

Peptide Library

Cyclic Peptide Library

Publications Citing Use of MedChemExpress (MCE) Melanotan (MT)-II

Voir tous les produits spécifiques à Isoform Melanocortin Receptor

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Melanotan (MT)-II

Macrocyclic Compound Library

Peptide Library

Cyclic Peptide Library

Publications Citing Use of MedChemExpress (MCE) Melanotan (MT)-II

Voir tous les produits spécifiques à Isoform Melanocortin Receptor

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Melanotan (MT)-II Related Classifications

HY-P0267 Related Classifications